biologic

Amphadase

hyaluronidase

Loss of exclusivityOctober 2016projected — 12-year biologic exclusivity estimate
CompanyAmphastar PharmaceuticalsSee this company's full patent-cliff portfolio

Drug detail

Brand nameAmphadase
Active ingredienthyaluronidase
Strength150UNITS/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalOctober 2004
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Amphadase patent cliff — loss of exclusivity October 2016 | CliffBio